ROS-responsive 18β-glycyrrhetic acid-conjugated polymeric nanoparticles mediate neuroprotection in ischemic stroke through HMGB1 inhibition and microglia polarization regulation

Jin, Lai; Zhu, Zhixin; Ling, Hong; Zhang, Qian; Wang, Fang; Mao, Zhengwei

doi:10.1016/j.bioactmat.2022.03.040

Cited by 52 publications

(38 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Diethylamine ethyl dextran (DEAE-dextran) is a kind of polyanionic reagent with high specificity. Based on DEAEdextran, Jin et al designed ROS-responsive 18β-glycyrrhetic acid-conjugated polymeric nanoparticles (DGA), which mediated neuroprotection of ischemic stroke through HMGB1 (high mobility group Box 1) (Jin et al, 2023). Microglia, an important innate immune component of CNS, is a double-edged sword in nerve damage because of its polarization between proinflammatory and anti-inflammatory properties.…”

Section: Natural Polymersmentioning

confidence: 99%

“…Therefore, nanoparticles loaded with 18β-glycyrrhetinic acid (GA) could inhibit expression of HMGB1. DGA successfully improved low solubility and short biological half-life of GA, and significantly reduced the infarct volume (Jin et al, 2023). Similarly, dextran and erythrocyte membranes were synthesized into bioengineered borate modified dextran polymer nanoparticles (SHP-RBC-NP) with ROS-responsive behaviors.…”

Section: Natural Polymersmentioning

confidence: 99%

See 1 more Smart Citation

Advances in the research of nano delivery systems in ischemic stroke

Wang²,

Jin³

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Ischemic stroke is the most common type of cerebrovascular disease with high disability rate and mortality. The blood-brain barrier (BBB) protects the homeostasis of the brain’s microenvironment and impedes the penetration of 98% of drugs. Therefore, effective treatment requires the better drug transport across membranes and increased drug distribution. Nanoparticles are a good choice for drugs to cross BBB. The main pathways of nano delivery systems through BBB include passive diffusion, adsorption-mediated endocytosis, receptor-mediated transport, carrier-mediated transport, etc. At present, the materials used in brain-targeted delivery can be divided into natural polymer, synthetic polymers, inorganic materials and phospholipid. In this review, we first introduced several ways of nano delivery systems crossing the BBB, and then summarized their applications in ischemic stroke. Based on their potential and challenges in the treatment of ischemic stroke, new ideas and prospects are proposed for designing feasible and effective nano delivery systems.

show abstract

Section: Natural Polymersmentioning

confidence: 99%

Section: Natural Polymersmentioning

confidence: 99%

Advances in the research of nano delivery systems in ischemic stroke

Wang²,

Jin³

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…As nanomaterials provide a more extended temporal window for therapeutic efficacy, novel techniques for vascular protection and angiogenesis during subacute stroke are being developed to address these issues. It is polymeric NPs that are most frequently used to deliver angiogenic agents in the subacute phase of acute ischemic strokes [ 27 , 109 , 298 ]. Various polymeric materials have distinct physicochemical qualities that rely on the characteristics of the basic building block that they are constructed from.…”

Section: Ischemia Strokementioning

confidence: 99%

Effective treatment of intractable diseases using nanoparticles to interfere with vascular supply and angiogenic process

et al. 2022

View full text Add to dashboard Cite

Angiogenesis is a vital biological process involving blood vessels forming from pre-existing vascular systems. This process contributes to various physiological activities, including embryonic development, hair growth, ovulation, menstruation, and the repair and regeneration of damaged tissue. On the other hand, it is essential in treating a wide range of pathological diseases, such as cardiovascular and ischemic diseases, rheumatoid arthritis, malignancies, ophthalmic and retinal diseases, and other chronic conditions. These diseases and disorders are frequently treated by regulating angiogenesis by utilizing a variety of pro-angiogenic or anti-angiogenic agents or molecules by stimulating or suppressing this complicated process, respectively. Nevertheless, many traditional angiogenic therapy techniques suffer from a lack of ability to achieve the intended therapeutic impact because of various constraints. These disadvantages include limited bioavailability, drug resistance, fast elimination, increased price, nonspecificity, and adverse effects. As a result, it is an excellent time for developing various pro- and anti-angiogenic substances that might circumvent the abovementioned restrictions, followed by their efficient use in treating disorders associated with angiogenesis. In recent years, significant progress has been made in different fields of medicine and biology, including therapeutic angiogenesis. Around the world, a multitude of research groups investigated several inorganic or organic nanoparticles (NPs) that had the potential to effectively modify the angiogenesis processes by either enhancing or suppressing the process. Many studies into the processes behind NP-mediated angiogenesis are well described. In this article, we also cover the application of NPs to encourage tissue vascularization as well as their angiogenic and anti-angiogenic effects in the treatment of several disorders, including bone regeneration, peripheral vascular disease, diabetic retinopathy, ischemic stroke, rheumatoid arthritis, post-ischemic cardiovascular injury, age-related macular degeneration, diabetic retinopathy, gene delivery-based angiogenic therapy, protein delivery-based angiogenic therapy, stem cell angiogenic therapy, and diabetic retinopathy, cancer that may benefit from the behavior of the nanostructures in the vascular system throughout the body. In addition, the accompanying difficulties and potential future applications of NPs in treating angiogenesis-related diseases and antiangiogenic therapies are discussed.

show abstract

“…With the aging of society, neurological diseases have become one of the leading causes of human death or disability, and it is difficult to fully restore the original neurological functions with existing treatments ( 5 ). An increasing amount of evidence shows that mitochondrial dynamics are involved in the occurrence and development of various neurological diseases ( 2 ).…”

Section: Introductionmentioning

confidence: 99%

Mitochondrial dynamics in neurological diseases: a narrative review

Shen¹,

Wen-li²,

Li³

et al. 2023

Ann Transl Med

View full text Add to dashboard Cite

Background and Objective: The mitochondrion is a crucial organelle for aerobic respiration and energy metabolism. It undergoes dynamic changes, including changes in its shape, function, and distribution through fission, fusion, and movement. Under normal conditions, mitochondrial dynamics are in homeostasis. However, once the balance is upset, the nervous system, which has high metabolic demands, will most likely be affected. Recent studies have shown that the imbalance of mitochondrial dynamics is involved in the occurrence and development of various neurological diseases. However, whether the regulation of mitochondrial dynamics can be used to treat neurological diseases is still unclear. We aimed to comprehensively analyze mitochondrial dynamics regulation and its potential role in the treatment of neurological diseases.Methods: A comprehensive literature review was carried out to understand the mechanisms and applications of mitochondrial dynamics in neurological diseases based on the literature available in PubMed, Web of Science, and Google Scholar.

show abstract

ROS-responsive 18β-glycyrrhetic acid-conjugated polymeric nanoparticles mediate neuroprotection in ischemic stroke through HMGB1 inhibition and microglia polarization regulation

Cited by 52 publications

References 75 publications

Advances in the research of nano delivery systems in ischemic stroke

Advances in the research of nano delivery systems in ischemic stroke

Effective treatment of intractable diseases using nanoparticles to interfere with vascular supply and angiogenic process

Mitochondrial dynamics in neurological diseases: a narrative review

Contact Info

Product

Resources

About